Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus csDMARDs vs csDMARDs alone for inhibition of bone erosion in rheumatoid arthritis (HR-pQCT)
jRCTs071180018Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of denosumab in rheumatoid arthritis (RA) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Apr 2018; status: completed.
02
Drugs
denosumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071180018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180018.